猴痘(Mpox)需要持续监测、疫苗、治疗药物和缓解策略
2022年识别的猴痘病毒(MPXV)广泛暴发对全球公共卫生系统构成新挑战,超过86,000人感染。经典公共卫生措施和疫苗接种减缓了病毒传播,但2023年3月仍有28个国家报告病例。疫苗和药物在动物模型中有效,但在当前暴发环境中的有效性所知甚少。作者提出六项优先行动,并强调大流行防范计划需额外协调和资源。
要点
- 2022年MPXV暴发超过86,000人感染,2023年3月仍有28个国家报告病例。
- 经典公共卫生措施和疫苗接种减缓了传播,但病毒可能进化并扩散至当前风险群体之外。
- 疫苗和药物在动物模型中有效性已确立,但在当前暴发环境中的有效性所知甚少。
核心结论
- MPXV暴发是对大流行防范计划的警告,需额外协调和资源,必须为持续传播、复燃和反复溢出做准备。
研究设计与样本
- 本文为综述,描述可用于预防和治疗MPXV感染的疫苗和药物,并阐述优先行动。
主要发现
- 2022年识别的MPXV广泛暴发已感染超过86,000人,令人担忧MPXV可能在原地理区域之外成为地方性流行病。
- 经典公共卫生措施(如隔离、接触者追踪和检疫)和疫苗接种减缓了病毒传播,但2023年3月28个国家仍有病例报告。
- 疫苗和药物在动物模型中对猴痘(mpox)的有效性已确立,但在当前暴发环境中的有效性所知甚少。
- 持续传播机会引发对病毒进化和扩散至当前风险群体之外的担忧。
关键数值与推荐
- 优先行动1:必须收集更多关于疫苗和药物在感染人类中有效性的数据。
- 优先行动2:全球合作必要,确保政府当局与发达国家和中低收入国家(LMICs)的私营部门合作提供治疗和疫苗,尤其是在历史上地方性流行/动物疫源地区。
- 优先行动3:必须增强诊断和监测能力,以识别病毒存在和可能引发复燃的地区和人群。
- 优先行动4:重症结局高风险者(如免疫受损、未经治疗的HIV、孕妇和炎症性皮肤病患者)必须被告知感染风险并保护其免受MPXV社区传播。
- 优先行动5:需要以非污名化方式与受打击最严重的社区接触,以提高对公共卫生措施的理解和接受。
临床怎么用
- 原文未据此给出推荐。
局限性
- 疫苗和药物在动物模型中对猴痘(mpox)的有效性已确立,但在当前暴发环境中的有效性所知甚少。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The widespread outbreak of the monkeypox virus (MPXV) recognized in 2022 poses new challenges for public healthcare systems worldwide. With more than 86,000 people infected, there is concern that MPXV may become endemic outside of its original geographical area leading to repeated human spillover infections or continue to be spread person-to-person. Fortunately, classical public health measures (e.g., isolation, contact tracing and quarantine) and vaccination have blunted the spread of the virus, but cases are continuing to be reported in 28 countries in March 2023. We describe here the vaccines and drugs available for the prevention and treatment of MPXV infections. However, although their efficacy against monkeypox (mpox) has been established in animal models, little is known about their efficacy in the current outbreak setting. The continuing opportunity for transmission raises concerns about the potential for evolution of the virus and for expansion beyond the current risk groups. The priorities for action are clear: 1) more data on the efficacy of vaccines and drugs in infected humans must be gathered; 2) global collaborations are necessary to ensure that government authorities work with the private sector in developed and low and middle income countries (LMICs) to provide the availability of treatments and vaccines, especially in historically endemic/enzootic areas; 3) diagnostic and surveillance capacity must be increased to identify areas and populations where the virus is present and may seed resurgence; 4) those at high risk of severe outcomes (e.g., immunocompromised, untreated HIV, pregnant women, and inflammatory skin conditions) must be informed of the risk of infection and be protected from community transmission of MPXV; 5) engagement with the hardest hit communities in a non-stigmatizing way is needed to increase the understanding and acceptance of public health measures; and 6) repositories of monkeypox clinical samples, including blood, fluids, tissues and lesion material must be established for researchers. This MPXV outbreak is a warning that pandemic preparedness plans need additional coordination and resources. We must prepare for continuing transmission, resurgence, and repeated spillovers of MPXV.
引用
- Roper RL, Garzino-Demo A, Del Rio C, et al. Monkeypox (Mpox) requires continued surveillance, vaccines, therapeutics and mitigating strategies. Vaccine. 2023. PMID: 37088603. doi:10.1016/j.vaccine.2023.04.010
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。